Nicholas A Weirath

Dr. Nicholas A Weirath

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2022 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
NWNicholas A Weirath
Nicholas A Weirath
AHAlexander K. Hurben
Alexander K. Hurben
CCChristopher Chao
Christopher Chao
SPSuresh S. Pujari
Suresh S. Pujari
TCTao Cheng
Tao Cheng
NTNatalia Tretyakova
Natalia Tretyakova

Verified
Journal Article
Open access
PDF file
QHQiyuan Han
Qiyuan Han
JFJenna Fernandez
Jenna Fernandez
ARAndrew Rajczewski
Andrew Rajczewski
TKThomas J.Y. Kono
Thomas J.Y. Kono
NWNicholas A Weirath
Nicholas A Weirath
NTNatalia Tretyakova
Natalia Tretyakova
Lung cancer remains a major contributor to cancer fatalities, with cigarette smoking known to be responsible for up to 80% of cases. Based on the ability of cigarette smoke to induce inflammation in the lungs and increased lung cancer incidence in smokers with inflammatory conditions such as COPD, we hypothesized that inflammation plays an important role in the carcinogenicity of cigarette smoke. To test this hypothesis, we performed multi-omic analyses of Type II pneumocytes of A/J mice exposed to cigarette smoke for various time periods. We found that cigarette smoke exposure resulted in significant changes in DNA methylation and hydroxymethylation, gene expression patterns, and protein abundance that were partially reversible and contributed to an inflammatory and potentially oncogenic phenotype.

26 August 2024 in ACS Pharmacology & Translational Science
Verified
Journal Article
Closed access
NWNicholas A Weirath
Nicholas A Weirath
Carrie Haskell-LuevanoCarrie Haskell-Luevano
Carrie Haskell-Luevano

20 January 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
NWNicholas A Weirath
Nicholas A Weirath
JZJonathan W. P. Zajac
Jonathan W. P. Zajac
HDHaley M. Donow
Haley M. Donow
TLTravis M. Lavoi
Travis M. Lavoi
CPClemencia Pinilla
Clemencia Pinilla
Carrie Haskell-LuevanoCarrie Haskell-Luevano
Carrie Haskell-Luevano

Verified
Journal Article
Open access
PDF file
JFJenna Fernandez
Jenna Fernandez
QHQiyuan Han
Qiyuan Han
ARAndrew Rajczewski
Andrew Rajczewski
TKThomas Kono
Thomas Kono
NWNicholas A Weirath
Nicholas A Weirath
NTNatalia Tretyakova
Natalia Tretyakova
Chronic inflammation plays a central role in the pathogenesis of lung diseases including asthma, long COVID, chronic obstructive pulmonary disease (COPD), and lung cancer. Lipopolysaccharide (LPS) is a potent inflammatory agent produced by Gram-negative bacteria and also found in cigarette smoke. Our earlier study revealed that the intranasal exposure of A/J mice to LPS for 7 days altered gene expression levels in alveolar Type II epithelial cells (AECIIs), which serve as precursors to lung adenocarcinoma and are also preferentially targeted by SARS-CoV-2. In the present work, we employed a comprehensive multi-omics approach to characterize changes in DNA methylation/hydroxymethylation, gene expression, and global protein abundances in the AECIIs of A/J mice following the sub-chronic exposure to LPS and after a 4-week recovery period. Exposure to LPS led to hypermethylation at regulatory elements within the genome such as enhancer regions and expression changes in genes known to play a role in lung cancer tumorigenesis. Changes in protein abundance were consistent with an inflammatory phenotype and also included tumor suppressor proteins. Integration of the multi-omics data resulted in a model where LPS-driven inflammation in AECIIs triggers epigenetic changes that, along with genetic mutations, may contribute to lung cancer development.

16 April 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
JFJenna Fernandez
Jenna Fernandez
QHQiyuan Han
Qiyuan Han
ARAndrew Rajczewski
Andrew Rajczewski
TKThomas Kono
Thomas Kono
NWNicholas A Weirath
Nicholas A Weirath
NTNatalia Tretyakova
Natalia Tretyakova
Chronic inflammation plays a central role in the pathogenesis of lung diseases including asthma, long COVID, chronic obstructive pulmonary disease (COPD), and lung cancer. Lipopolysaccharide (LPS) is a potent inflammatory agent produced by Gram-negative bacteria and also found in cigarette smoke. Our earlier study revealed that intranasal exposure of A/J mice to LPS for 7 days altered gene expression levels in alveolar type II epithelial cells (AECII), which serve as precursors to lung adenocarcinoma and are also preferentially targeted by SARS-CoV-2. In the present work, we employed a comprehensive multi-omics approach to characterize changes in DNA methylation/hydroxymethylation, gene expression, and global protein abundances in AECII of A/J mice following sub-chronic exposure to LPS and after 4-week recovery period. Exposure to LPS led to hypermethylation at regulatory elements within the genome such as enhancer regions and led to expression changes in genes known to play a role in lung cancer tumorigenesis. Changes in protein abundance were consistent with an inflammatory phenotype but also included tumor suppressor proteins. Integration of the multi-omics data resulted in a model where LPS-driven inflammation in AECII triggers epigenetic changes that, along with genetic mutations, contribute to lung cancer development.